Señales en vivo de HCYT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 jul 2023 @ 15:00):

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States...

Stats
Volumen de hoy	325.00
Volumen promedio	796.00
Capitalización de mercado	624 980
EPS	$-0.727 ( 2023-11-13 )
Próxima fecha de ganancias	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0642
ATR14	$0.236 (23.60%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-16	Wagner Todd R	Sell	303 107 000	SERIES A PREFERRED STOCK
2024-01-16	Wagner Todd R	Buy	303 107	COMMON STOCK
2024-01-16	Farrior J Rex Iii	Sell	13 168 000	SERIES A PREFERRED STOCK
2024-01-16	Farrior J Rex Iii	Buy	13 168	COMMON STOCK
2022-03-21	Lynch Frederick J	Sell	8 321 785	STOCK PURCHASE WARRANTS

INSIDER POWER
-99.80
Last 90 transactions
Buy: 833 204 294 \| Sell: 379 884 747

Volumen Correlación

Largo: -0.31 (neutral)

Corto: 0.58 (weak)

Signal:(32.745) Neutral

H-CYTE, Inc. Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

H-CYTE, Inc. Correlación - Moneda/Commodity

0.05
( neutral )

0.16
( neutral )

0.00
( neutral )

0.19
( neutral )

-0.36
( neutral )

-0.15
( neutral )

H-CYTE, Inc. Finanzas

Annual	2022
Ingresos:	$453 460
Beneficio Bruto:	$335 859 (74.07 %)
EPS:	$-49.51

FY	2022
Ingresos:	$453 460
Beneficio Bruto:	$335 859 (74.07 %)
EPS:	$-49.51

FY	2021
Ingresos:	$1.61M
Beneficio Bruto:	$906 813 (56.27 %)
EPS:	$-30.00

FY	2020
Ingresos:	$2.15M
Beneficio Bruto:	$1.38M (64.34 %)
EPS:	$-60.00

Financial Reports:

No articles found.

H-CYTE, Inc.

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.